drugset / Trial / NCT06096974
Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS
NaSequentialOpen-labelTreatment
Summary
This study will evaluate the safety, tolerability, drug levels, pharmacodynamic effects, and clinical activity of YL 17231 in patients with advanced solid tumors harboring mutations in KRAS, HRAS, or NRAS.
Timeline
- Start
- 2023-10-24
- Primary completion
- 2025-10
- Completion
- 2026-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | YL-17231 | Unknown | 0.25 mg | Oral |